KR20160074018A - Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법 - Google Patents

Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법 Download PDF

Info

Publication number
KR20160074018A
KR20160074018A KR1020167016288A KR20167016288A KR20160074018A KR 20160074018 A KR20160074018 A KR 20160074018A KR 1020167016288 A KR1020167016288 A KR 1020167016288A KR 20167016288 A KR20167016288 A KR 20167016288A KR 20160074018 A KR20160074018 A KR 20160074018A
Authority
KR
South Korea
Prior art keywords
compound
administration
acceptable salt
pharmaceutically acceptable
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167016288A
Other languages
English (en)
Korean (ko)
Inventor
브리안 피. 카니
아쯔유끼 가께에
이사오 가와구찌
Original Assignee
길리애드 사이언시즈, 인코포레이티드
니뽄 다바코 산교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 길리애드 사이언시즈, 인코포레이티드, 니뽄 다바코 산교 가부시키가이샤 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20160074018A publication Critical patent/KR20160074018A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167016288A 2005-12-30 2006-12-29 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법 Ceased KR20160074018A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75503905P 2005-12-30 2005-12-30
US60/755,039 2005-12-30
US75663106P 2006-01-06 2006-01-06
US60/756,631 2006-01-06
US76390106P 2006-02-01 2006-02-01
US60/763,901 2006-02-01
PCT/US2006/049668 WO2007079260A1 (en) 2005-12-30 2006-12-29 Methods for improving the pharmacokinetics of hiv integrase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147014797A Division KR20140082858A (ko) 2005-12-30 2006-12-29 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법

Publications (1)

Publication Number Publication Date
KR20160074018A true KR20160074018A (ko) 2016-06-27

Family

ID=38016698

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020087018651A Active KR101524165B1 (ko) 2005-12-30 2006-12-29 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
KR1020167016288A Ceased KR20160074018A (ko) 2005-12-30 2006-12-29 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
KR1020147014797A Ceased KR20140082858A (ko) 2005-12-30 2006-12-29 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020087018651A Active KR101524165B1 (ko) 2005-12-30 2006-12-29 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147014797A Ceased KR20140082858A (ko) 2005-12-30 2006-12-29 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법

Country Status (16)

Country Link
US (1) US20070219243A1 (OSRAM)
EP (2) EP1976517A1 (OSRAM)
JP (1) JP4676536B2 (OSRAM)
KR (3) KR101524165B1 (OSRAM)
CN (1) CN104069108A (OSRAM)
AP (1) AP2702A (OSRAM)
AU (1) AU2006332664B2 (OSRAM)
BR (1) BRPI0620865A2 (OSRAM)
CA (2) CA2847871C (OSRAM)
EA (2) EA018544B1 (OSRAM)
HR (1) HRP20080313A2 (OSRAM)
IL (1) IL192208A (OSRAM)
NO (1) NO20083333L (OSRAM)
NZ (1) NZ569576A (OSRAM)
SG (2) SG170795A1 (OSRAM)
WO (1) WO2007079260A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
LT2487163T (lt) 2007-02-23 2016-10-25 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
EP2167088A1 (en) * 2007-06-29 2010-03-31 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
JP5547067B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
WO2009092002A1 (en) * 2008-01-17 2009-07-23 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids
PT3494972T (pt) * 2010-01-27 2024-02-12 Viiv Healthcare Co Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (OSRAM) 2013-07-12 2018-07-21
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (OSRAM) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
CN110790773A (zh) 2015-04-02 2020-02-14 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
CA2948021C (en) 2015-11-09 2024-06-18 Gilead Sciences, Inc. Pharmaceutical formulations of (2r,5s,13 ar)-8hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzy1)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1'2':4,5]pyrazino [2,1-b][1,3] oxazepine-10-carboxamide
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
DE674513T1 (de) * 1992-12-29 1996-01-18 Abbott Lab Inhibitoren der retroviralen protease.
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
ES2324549T5 (es) * 1999-06-04 2012-10-31 Abbott Laboratories Solución farmacéutica que comprende ritonavir, un disolvente (ácido graso de cadena larga) y agua
US6541515B2 (en) 2000-08-09 2003-04-01 Merck & Co., Inc. HIV integrase inhibitors
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
AU2003301439A1 (en) * 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
SI1564210T1 (sl) * 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
BRPI0407052A (pt) * 2003-01-27 2006-01-17 Pfizer Inibidores da hiv-integrase, composições farmacêuticas, e métodos para sua utilização
US7812016B2 (en) * 2003-05-13 2010-10-12 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
EP2332538A1 (en) 2004-05-21 2011-06-15 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
US8119602B2 (en) * 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
CA2661943C (en) * 2006-09-12 2015-11-03 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
JP5547067B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
EP2167088A1 (en) * 2007-06-29 2010-03-31 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa

Also Published As

Publication number Publication date
AU2006332664A1 (en) 2007-07-12
NO20083333L (no) 2008-09-29
WO2007079260A9 (en) 2007-08-30
EP1976517A1 (en) 2008-10-08
HRP20080313A2 (en) 2008-11-30
CA2847871C (en) 2016-07-26
JP4676536B2 (ja) 2011-04-27
CA2635468C (en) 2016-08-09
IL192208A (en) 2013-10-31
KR101524165B1 (ko) 2015-06-01
CA2635468A1 (en) 2007-07-12
CA2847871A1 (en) 2007-07-12
WO2007079260A1 (en) 2007-07-12
SG170796A1 (en) 2011-05-30
KR20080081358A (ko) 2008-09-09
US20070219243A1 (en) 2007-09-20
BRPI0620865A2 (pt) 2011-11-29
IL192208A0 (en) 2009-02-11
AU2006332664B2 (en) 2013-03-14
EA201201496A1 (ru) 2013-07-30
NZ569576A (en) 2011-09-30
EP2308490A1 (en) 2011-04-13
CN104069108A (zh) 2014-10-01
KR20140082858A (ko) 2014-07-02
JP2009525265A (ja) 2009-07-09
AP2702A (en) 2013-07-23
EA200801619A1 (ru) 2008-10-30
AP2008004522A0 (en) 2008-06-30
EA018544B1 (ru) 2013-08-30
SG170795A1 (en) 2011-05-30

Similar Documents

Publication Publication Date Title
KR101524165B1 (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
JP5769763B2 (ja) 治療用組成物およびその使用
JP5769762B2 (ja) 治療組成物およびその使用
EP1458447B1 (en) Combination of cytochome p 450 dependent protease inhibitors
US20190358240A1 (en) Hiv treatment formulation of atazanavir and cobicistat
US20090233964A1 (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2013203476B2 (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
HK1156259A (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
HK40002830B (en) Hiv treatment formulation of atazanavir and cobicistat
HK40002830A (en) Hiv treatment formulation of atazanavir and cobicistat
HK1070008B (en) Combination of cytochome p 450 dependent protease inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160617

Application number text: 1020147014797

Filing date: 20140530

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160718

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160725

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170124

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160725

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I